FOXP3 (Forkhead box protein P3) is mainly expressed in Regulatory T (Treg) cells, a subset of CD4+ T-cells, that play a suppressive role in the immune system. Treg cells ensure immune homeostasis through their ability to suppress the activation and function of leukocytes. FOXP3 has emerged as a prominent target for the development of new immunotherapies for cancer and autoimmune diseases.
LAG3 (Lymphocyte activation gene-3, CD223) plays an important role in modulating T cell expansion and function. Interestingly, LAG-3 bears structural homology to CD4 and functions as a cell surface molecule expressed on activated T cells. Blockade of LAG-3 can augment T cell function. Moreover, several preclinical and clinical studies suggest a role for LAG-3 blocking antibodies in cancer immunotherapy.
TIGIT - more clones
The complexity of the TIGIT axis in immune oncology has increased the demand for different antibody clones targeting different immunogenic motifs.
CD112R is preferentially expressed on T-cells and inhibits T-cell receptor mediated signals. Blockade of the CD112R-CD112 interaction enhances T cell response.
CD226 - different clones
CD226 and TIGIT share ligands and binding of CD155 and CD112 has different impact on T cell responses. This complexity may be investigated with different antibody clones targeting different immunogenic motifs.
CD155 - different clones
CD155 acts as the ligand for both costimulatory receptor CD226 and coinhibitory receptor TIGIT and CD96 on natural killer and T cells. This complexity may be investigated with different antibody clones targeting different immunogenic motifs.
CD73, together with CD39, plays an important role in promoting immunosuppression through the pathway degrading ATP into adenosine, which has a significant effect on the tumor microenvironment. Theses cell surface enzymes have emerged as novel therapeutic targets to enhance antitumor immune responses across a wide range of tumors.
TIGIT - clone TG1
Clone TG1 immunohistochemistry allows the identification of invading TIGIT positive T-cells in routine fixed FFPE human tumor tissues.
Tumor IHC marker
CD138 - clone JASY1
Clone JASY1 has been validated for detection of CD138 in routine fixed FFPE tissues with focus to identify plasma cells and to monitor CD138 expression levels in tumors.
p16- clone JAP16
Clone JAP16 has been validated for detection of p16 INK4 in routine fixed FFPE tissues with focus on gynecological pathology.
PAX8- clone JAX8
Clone JAX8 has been validated for detection of the transcription factor PAX8 in routine fixed FFPE tissues with a focus on Ovarian Carcinoma, Thyroid Carcinoma and Renal Cell Carcinoma.
BSEP - clone JAP11
PD-1 - clone JAD1
PD-L1 - clone JAL1
MUC-5 - clone JAC5